AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer
The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.
Breast Cancer|Low Bone Mineral Density|Osteopenia
DRUG: Placebo|DRUG: AMG 162 / Denosumab
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12, Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry., 12 months
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 6, Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry., 6 months|Total Hip Bone Mineral Density Percent Change From Baseline at Month 12, Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry., 12 months|Total Hip Bone Mineral Density Percent Change From Baseline at Month 6, Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry., 6 months|Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12, Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry., 12 months|Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 6, Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry., 6 months
The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.